SCHEMBL5546401

SCHEMBL5546401

O=C(NCC1CO1)OCc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
AIMP2 Q13155 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
CCKBR P32239 1/20 0.42
HSD17B10 Q99714 1/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 2/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41
MAPT P10636 1/20 0.40
GRIN2B Q13224 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542852 0.86 SMN1; SMN2 (0.47) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL6154117 0.85 LMNA (0.55) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL633304 0.85 LMNA (0.55) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL633303 0.85 LMNA (0.55) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL1502037 0.77 DRD4 (0.59) LMNAMEN1KMT2AALDH1A1CYP2C19
SCHEMBL13897189 0.75 CYP1A2 (0.50) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL8802747 0.74 LMNA (0.56) LMNASMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL5540914 0.72 HTR2A (0.40) LMNAKDM4ESMN1; SMN2L3MBTL1MEN1
SCHEMBL17064147 0.72 PLAU (0.64) POLBLMNASMN1; SMN2L3MBTL1KMT2A
SCHEMBL3434164 0.72 PLAU (0.64) POLBLMNASMN1; SMN2L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885LMNA 4152/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.